<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; Sepracor</title>
	<atom:link href="http://www.stockbloghub.com/tag/sepracor/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Thu, 24 May 2012 23:16:35 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(SEPR) Top Small-Cap Equity Funds &#8211; Mutual Fund Commentary</title>
		<link>http://www.stockbloghub.com/2009/10/16/sepr-top-small-cap-equity-funds-mutual-fund-commentary-2/17731</link>
		<comments>http://www.stockbloghub.com/2009/10/16/sepr-top-small-cap-equity-funds-mutual-fund-commentary-2/17731#comments</comments>
		<pubDate>Sat, 17 Oct 2009 00:04:17 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Charles River Laboratories International Inc]]></category>
		<category><![CDATA[CRL]]></category>
		<category><![CDATA[Medarex Inc]]></category>
		<category><![CDATA[MEDX]]></category>
		<category><![CDATA[SEPR]]></category>
		<category><![CDATA[Sepracor]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=17731</guid>
		<description><![CDATA[Today we are featuring top-performing “Small-Cap&#8221; equity mutual funds, which primarily invest in equity securities of companies that have market capitalizations of less than $2 billion. Investors can find such funds by checking out the entire list of the Zacks #1 Rank Small-Cap Equity Funds. 2 Solid Picks Dean Small Cap Value A (DASCX) seeks long-term capital appreciation and secondarily, dividend income. The fund focuses on high-quality companies that are undervalued for transitory reasons in search of above-average returns. The fund may invest in equity securities of mid or large-cap companies, preferred stocks, or derivative instruments, such as put and call options and futures contracts, and in fixed-income securities Incorporatedluding corporate bonds. Unit holders have to make a minimum initial investment of $1,000 to enter this Zacks#1 Rank (“Strong Buy&#8221;) ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/10/16/sepr-top-small-cap-equity-funds-mutual-fund-commentary-2/17731/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(SEPR) Dainippon-Sepracor Deal Emerges</title>
		<link>http://www.stockbloghub.com/2009/10/15/sepr-dainippon-sepracor-deal-emerges/17778</link>
		<comments>http://www.stockbloghub.com/2009/10/15/sepr-dainippon-sepracor-deal-emerges/17778#comments</comments>
		<pubDate>Thu, 15 Oct 2009 21:17:55 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[CNS]]></category>
		<category><![CDATA[Cohen & Steers Inc.]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Schering-Plough Corporation]]></category>
		<category><![CDATA[SEPR]]></category>
		<category><![CDATA[Sepracor]]></category>
		<category><![CDATA[SGP]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=17778</guid>
		<description><![CDATA[Today, Dainippon Sumitomo and Sepracor (SEPR) have announced the successful completion of the initial share offering period, where almost 78.2% of Sepracor’s shares were tendered. The offer period has been extended to Oct 19, 2009, to enable other shareholders to tender their shares as well. As a reminder, in September, the Japanese pharmaceutical company Dainippon Sumitomo Pharma Co had announced a deal to acquire Sepracor at $23 per share or $2.6 billion. However, soon after the announcement, shareholders of Sepracor filed a suit in a Delaware court against the company, citing the offered price as inadequate. They were seeking the court’s intervention to stop the deal and pay damages. Additionally, certain aspects of the deal were against the interest of Sepracor’s shareholders. The deal included a $77.4 million termination fee ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/10/15/sepr-dainippon-sepracor-deal-emerges/17778/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BMY) Bristol Myers Squibb Sells Indonesian Unit</title>
		<link>http://www.stockbloghub.com/2009/09/16/bmy-bristol-myers-squibb-sells-indonesian-unit/15384</link>
		<comments>http://www.stockbloghub.com/2009/09/16/bmy-bristol-myers-squibb-sells-indonesian-unit/15384#comments</comments>
		<pubDate>Wed, 16 Sep 2009 22:34:04 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Featured]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[SEPR]]></category>
		<category><![CDATA[Sepracor]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=15384</guid>
		<description><![CDATA[Bristol Myers Squibb (BMY) yesterday announced that it would sell the Asian rights to its over-the-counter (OTC) drugs to Japan&#8217;s Taisho Pharmaceutical for $160 million. Taisho will also buy Bristol’s Indonesian unit, which manufactures and sells OTC and ethical pharmaceutical products, for $150 million. The deal is expected to close during the fourth quarter of this year. This is the latest in a series of deals signed by Bristol to focus on prescription drugs. Through this deal, the Japanese firm seeks to bolster its presence in markets where demand for self-medicating products is still growing. Furthermore, this transaction will help Japan&#8217;s biggest maker of non-prescription drugs to make its first full-fledged entry into Asia&#8217;s OTC drug market. The transaction  will enable Taisho to acquire certain product registrations, trademarks and related ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/09/16/bmy-bristol-myers-squibb-sells-indonesian-unit/15384/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

